EB
TVTX icon

Eastern Bank’s Travere Therapeutics TVTX Stock Holding History

Eastern Bank’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.5K Hold
325
– – ﹤0.01% 789
2026
Q1 		$9.66K Buy
+325
New +$9.71K ﹤0.01% 855

Other funds holding TVTX

SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Eastern Bank's TVTX Position: Q2 2026 in Review

Eastern Bank held its Travere Therapeutics (TVTX) position steady in Q2 2026 at 325 shares worth $18.5K. The position accounts for ﹤0.01% of the portfolio, ranked #789.

Eastern Bank first reported a position in TVTX in Q1 2026 and has held it in 2 quarters since. 55 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Eastern Bank held 325 shares of Travere Therapeutics worth $18.5K as of Q2 2026.
  • Eastern Bank left its Travere Therapeutics share count unchanged in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Eastern Bank's portfolio in Q2 2026, its #789 holding.
  • Eastern Bank first reported a position in Travere Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 55 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Eastern Bank's 13F filing for Q2 2026, filed 1 Jul 2026.